AJ 303
Alternative Names: AJ-303Latest Information Update: 28 Mar 2025
At a glance
- Originator AnnJi Pharmaceutical
- Class Anti-inflammatories; Antifibrotics
- Mechanism of Action HDAC6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in Taiwan (PO)
- 23 Feb 2021 AnnJi Pharmaceutical plans a clinical trial for Idiopathic pulmonary fibrosis in 2021 (AnnJi Pharmaceutical pipeline, February 2021)
- 01 Feb 2021 Preclinical trials in Idiopathic pulmonary fibrosis in Taiwan (PO) before February 2021 (AnnJi Pharmaceutical website, February 2021)